JOVAPAST. VACCINE

Indications

• Preoperative sedation
• Anxiety disorders
• Muscle relaxation during procedures

Dosage

Children: Refer to the BNF for Children for appropriate dosing recommendations based on age, weight, and clinical condition.

Adults: Refer to specific clinical guidelines and the BNF for detailed dosing information as it varies based on the procedure and individual patient characteristics.

Mechanism of action

Before works by potentiating the effects of GABA at the GABA-A receptor sites, leading to increased inhibitory neurotransmission. This results in sedation, anxiolysis, and muscle relaxation, which are beneficial during preoperative care. The drug may also influence other neurotransmitter systems, including serotonin and norepinephrine, contributing to its anxiolytic properties.

Pharmacodynamics

The pharmacodynamic profile of Before indicates a rapid onset of action, particularly when administered intravenously, with peak effects typically occurring within 30 minutes to 1 hour. The duration of action can vary, but it generally provides effective sedation for short surgical procedures. The anxiolytic effects can persist longer, aiding in preoperative anxiety management.

Pharmacokinetics

Before is rapidly absorbed after parenteral administration, with a bioavailability approaching 100% for intravenous routes. It is extensively metabolized in the liver through cytochrome P450 enzymes, primarily CYP3A4, resulting in various metabolites. The elimination half-life ranges from 2 to 6 hours, depending on individual patient factors such as age, liver function, and concurrent medications. Renal excretion plays a minor role in the clearance of the drug and its metabolites.

Pregnancy

Use only if clearly needed, as the effects on fetal development are not well established.

Breast-feeding

Use with caution, as it is not known if the drug is excreted in human milk.

Storage

Store at room temperature, away from moisture and heat.

Indications

• Bacterial meningitis
• Pneumonia
• Epiglottitis
• Otitis media
• Sinusitis
• Sepsis

Dosage

Children: Refer to the BNF for Children for age-appropriate dosing guidelines based on the specific antibiotic and clinical scenario.

Adults: Refer to specific antibiotic guidelines based on culture and sensitivity results, as well as the severity of the infection.

Mechanism of action

The mechanism of action of antibiotics used to treat infections caused by haemolytica involves inhibition of bacterial cell wall synthesis, protein synthesis, or nucleic acid synthesis, depending on the specific antibiotic. For instance, beta-lactam antibiotics target penicillin-binding proteins, disrupting cell wall formation, leading to cell death.

Pharmacodynamics

Pharmacodynamics of antibiotics against haemolytica involves their ability to inhibit bacterial growth (bacteriostatic) or kill bacteria (bactericidal), depending on the drug class. The efficacy of these agents is often evaluated based on their minimum inhibitory concentration (MIC) and their ability to achieve therapeutic concentrations at the site of infection.

Pharmacokinetics

Pharmacokinetics of antibiotics vary widely but generally encompass absorption, distribution, metabolism, and excretion (ADME) profiles. Many antibiotics are rapidly absorbed in the gastrointestinal tract, distributed widely in body tissues, and are excreted primarily via the kidneys. Half-lives can vary significantly, influencing dosing frequency.

Pregnancy

There is limited data on the use of haemolytica in pregnancy. Caution is advised, and it should be used only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

There is insufficient information regarding the safety of haemolytica during breastfeeding. Caution is recommended.

Storage

Store in a cool, dry place away from direct sunlight. Ensure it is kept out of reach of children.

Dosage

Children: Refer to specific drug guidelines for dosing, as inactivation does not have a standard dosage.

Adults: Refer to specific drug guidelines for dosing, as inactivation does not have a standard dosage.

Mechanism of action

Inactivation of drugs generally involves enzymatic conversion, where metabolic enzymes modify the drug's structure. This may include processes such as oxidation, reduction, hydrolysis, or conjugation, effectively altering the drug's chemical properties and reducing its pharmacological activity. The specific pathways and enzymes involved depend on the drug in question.

Pharmacodynamics

The pharmacodynamics of drug inactivation involves the relationship between drug concentration and effect. As a drug undergoes inactivation, its concentration decreases, leading to reduced therapeutic effects. This is crucial in determining dosing regimens and understanding drug interactions, as co-administered drugs may affect the rate of inactivation, either enhancing or diminishing the therapeutic response.

Pharmacokinetics

Pharmacokinetics of drug inactivation encompasses the absorption, distribution, metabolism, and excretion of drugs. Inactivation typically occurs during the metabolism phase, where the liver plays a significant role through phase I and phase II reactions. The rate of inactivation can vary greatly between individuals due to genetic factors, age, liver function, and the presence of other medications that may induce or inhibit metabolic enzymes.

Pregnancy

Inactivation refers to the process of rendering a drug inactive, which may vary based on the specific drug and its mechanism of metabolism. The implications during pregnancy depend on the drug being inactivated.

Breast-feeding

The effects of inactivation during breastfeeding are contextual and depend on the specific drug involved. Generally, if a drug is inactivated, it may have reduced transfer into breast milk, but this must be evaluated on a case-by-case basis.

Storage

Storage conditions for inactivation depend on the specific drug and its formulation. Generally, medications should be stored in accordance with their labeling, considering factors like temperature, light, and humidity.

Indications

• Bovine respiratory disease complex
• Ovine pneumonia
• Systemic infections in livestock

Dosage

Children: Refer to veterinary guidelines for appropriate dosing based on the specific antibiotic used and the severity of the infection.

Adults: Refer to veterinary guidelines for appropriate dosing based on the specific antibiotic used and the severity of the infection.

Mechanism of action

Mannheimia haemolytica produces several virulence factors, including leukotoxin, which targets and kills neutrophils, leading to immune system evasion. The bacterium also produces various enzymes and toxins that contribute to tissue damage and inflammation, promoting disease progression.

Pharmacodynamics

The pharmacodynamics of treatment against Mannheimia involve the use of antibiotics and anti-inflammatory agents. Antibiotics target the bacterial cell wall synthesis or protein synthesis, leading to bacterial cell death or growth inhibition. Anti-inflammatory drugs help mitigate the inflammatory response caused by the infection, reducing clinical signs and improving recovery rates in affected animals.

Pharmacokinetics

The pharmacokinetics of antibiotics effective against Mannheimia, such as tetracyclines or macrolides, vary based on the specific drug used. Generally, these agents are well-absorbed after administration, widely distributed throughout body tissues, and eliminated by renal or hepatic pathways. The half-life and duration of action depend on the specific antibiotic characteristics and the route of administration.

Pregnancy

There is limited data on the use of Mannheimia during pregnancy. Caution is advised when prescribing.

Breast-feeding

Safety during breastfeeding is not well established. Caution is recommended.

Storage

Store at room temperature, away from direct sunlight and moisture.

Indications

• Cellulitis
• Abscesses
• Respiratory infections
• Osteomyelitis
• Septic arthritis
• Endocarditis

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations tailored to pediatric patients.

Adults: Refer to specific guidelines or the BNF for appropriate antibiotic dosing based on the type and severity of the infection.

Mechanism of action

Pasteurella multocida produces several virulence factors, including polysaccharide capsules that inhibit phagocytosis, endotoxins that can cause inflammation, and a range of enzymes that facilitate tissue invasion. Antibiotics effective against Pasteurella, such as beta-lactams, inhibit cell wall synthesis, leading to bacterial lysis and death.

Pharmacodynamics

The pharmacodynamics of antibiotics used to treat infections caused by Pasteurella multocida are characterized by their ability to disrupt bacterial cell wall synthesis, inhibit protein synthesis, or interfere with nucleic acid synthesis. The effectiveness of these antibiotics is influenced by factors such as the bacterial strain's susceptibility, the site of infection, and the host's immune response.

Pharmacokinetics

The pharmacokinetics of antibiotics vary depending on the specific drug used to treat infections caused by Pasteurella multocida. Generally, antibiotics are absorbed and distributed throughout the body, with some achieving higher concentrations in tissues and fluids. Metabolism and excretion also vary; for instance, many beta-lactams are primarily excreted unchanged in the urine, necessitating dose adjustments in renal impairment.

Pregnancy

Safety during pregnancy has not been established. Use only if the benefits outweigh the risks.

Breast-feeding

It is unknown whether this drug is excreted in human breast milk. Caution is advised when administering to nursing mothers.

Storage

Store at room temperature, protected from light and moisture. Keep out of reach of children.

Indications

• Infectious diseases caused by bacteria
• Viral infections
• Fungal infections
• Parasitic infections

Dosage

Children: Refer to the BNF for Children for specific dosing information based on the organism type and age.

Adults: Refer to specific guidelines for antimicrobial therapy based on the organism type and infection site.

Mechanism of action

The mechanism of action of organisms varies widely depending on the type. For example, bacteria can reproduce rapidly and may produce toxins that interfere with host cellular functions. Viruses invade host cells and hijack cellular machinery to replicate. Fungi can disrupt cell membranes and evade the immune response. Each organism has unique pathways for infection, propagation, and interaction with host defenses.

Pharmacodynamics

Pharmacodynamics of organisms relates to their growth, replication, and the effects they have on the host. Pathogenic bacteria can elicit immune responses leading to inflammation. Viruses often induce cellular apoptosis or necrosis, while fungi can cause damage through their metabolic byproducts. The interaction between the organism and the host's immune system is crucial in determining the severity of the disease.

Pharmacokinetics

Pharmacokinetics of organisms is not applicable as they do not have a pharmacokinetic profile like drugs. Instead, their behavior in the host can be characterized by their replication rate, survival in various environments, and the ability to develop resistance to antimicrobial agents. The distribution of organisms in the body, their elimination through immune responses, and their potential to establish reservoirs or persistence in host tissues are critical.

Indications

• Cellulitis
• Abscess formation
• Respiratory tract infections
• Septic arthritis
• Osteomyelitis
• Systemic infections following animal bites

Dosage

Children: Refer to specific antibiotic guidelines for dosing based on the type and severity of infection.

Adults: Refer to specific antibiotic guidelines for dosing based on the type and severity of infection.

Mechanism of action

Pasteurella multocida can cause disease by evading host immune responses and producing virulence factors like polysaccharide capsules, endotoxins, and enzymes that disrupt host cell functions. These mechanisms enable the bacteria to adhere to host tissues, invade cells, and evade phagocytosis, contributing to its pathogenicity.

Pharmacodynamics

The pharmacodynamics of Pasteurella infections largely depend on the host's immune response and the antibiotics used for treatment. Pasteurella multocida is typically susceptible to a range of antibiotics, including beta-lactams, tetracyclines, and macrolides, but resistance can occur. Effective management of infections usually requires timely antibiotic therapy, particularly in cases of severe or systemic infection.

Pharmacokinetics

The pharmacokinetics of antibiotics used to treat Pasteurella infections varies by drug. Generally, these antibiotics are absorbed through the gastrointestinal tract, distributed widely in body tissues, and excreted primarily via renal pathways. The choice of antibiotic and its dosing regimen will depend on the severity of the infection, the patient's renal function, and the specific antibiotic used.

Pregnancy

There are no well-controlled studies in pregnant women. Use only if clearly needed.

Breast-feeding

Caution should be exercised when administered to a nursing mother.

Storage

Store at room temperature, away from moisture and heat.

Indications

• Bacterial infections
• Gastroenteritis caused by Salmonella serovars
• Typhoid fever caused by Salmonella Typhi
• Urinary tract infections caused by different E. coli serovars

Dosage

Children: Refer to specific antibiotic guidelines based on the identified serovar and its susceptibility profile.

Adults: Refer to specific antibiotic guidelines based on the identified serovar and its susceptibility profile.

Mechanism of action

Serovars themselves do not have a singular mechanism of action as they represent variations of bacterial strains. Each serovar may express different virulence factors, surface antigens, and mechanisms of resistance to antibiotics. These factors can influence how the bacteria interacts with the host immune system, adhere to host tissues, and cause disease.

Pharmacodynamics

The pharmacodynamics of treatment against serovars depend on the antibiotic or antimicrobial agent used and the specific characteristics of the serovar in question. Antibiotics may target specific bacterial processes such as cell wall synthesis, protein synthesis, or nucleic acid synthesis. The effectiveness of treatment can vary based on the serovar's resistance mechanisms and susceptibility patterns.

Pharmacokinetics

Pharmacokinetics will vary widely depending on the specific antibiotic used to treat infections caused by serovars. Factors such as absorption, distribution, metabolism, and excretion are crucial in determining the efficacy of treatment. Generally, pharmacokinetic properties are influenced by the route of administration, the patient's physiological state, and the presence of any co-morbid conditions.

Pregnancy

Safety during pregnancy has not been established. It is advised to assess the risk versus benefit before use.

Breast-feeding

Caution is advised when using during breastfeeding, as effects on the infant are unknown.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Dosage

Children: Refer to specific drug information for paediatric dosing guidelines.

Adults: Refer to specific drug information for adult dosing guidelines.

Mechanism of action

The mechanism of action of viable drugs can vary significantly based on the specific active ingredients. Generally, drugs classified as viable act through targeting specific biological pathways, receptors, or enzymes to elicit a desired therapeutic effect, often involving receptor binding, inhibition or stimulation of enzymatic activity, and modulation of cellular signaling pathways.

Pharmacodynamics

Pharmacodynamics of viable drugs involves understanding the relationship between drug concentration and effect. This includes examining how drugs interact with biological targets, the time course of their effects, and potential side effects. The efficacy of a drug is determined by its affinity for the target receptor and the subsequent physiological responses.

Pharmacokinetics

Pharmacokinetics encompasses the absorption, distribution, metabolism, and excretion (ADME) of viable drugs. Factors such as bioavailability, half-life, and clearance rates are crucial in determining the dosing regimen and therapeutic outcome. Each drug's pharmacokinetic profile influences how it is administered and the expected duration of its action.

Pregnancy

Use during pregnancy should be based on the assessment of potential benefits versus risks, as data on safety are limited.

Breast-feeding

Caution is advised when using during breastfeeding due to limited data on excretion in breast milk.

Storage

Store in a cool, dry place, away from light and moisture. Check specific product guidelines for optimal storage conditions.